Oncolysis of Multifocal Hepatocellular Carcinoma in the Rat Liver by Hepatic Artery Infusion of Vesicular Stomatitis Virus

Murray, 1996, Evidence-based health policy—lessons from the Global Burden of Disease Study, Science, 274, 740, 10.1126/science.274.5288.740 Parkin, 2001, Estimating the world cancer burden: Globocan 2000, Int. J. Cancer, 94, 153, 10.1002/ijc.1440 Parkin, 1984, Estimates of the worldwide frequency of twelve major cancers, Bull. World Health Organ, 62, 163 El-Serag, 1999, Rising incidence of hepatocellular carcinoma in the United States, N. Engl. J. Med., 340, 745, 10.1056/NEJM199903113401001 Jemal, 2002, Cancer statistics, 2002, CA Cancer J. Clin., 52, 23, 10.3322/canjclin.52.1.23 El-Serag, 2001, Epidemiology of hepatocellular carcinoma, Clin. Liver Dis., 5, 87, 10.1016/S1089-3261(05)70155-0 Alter, 2000, Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome, Semin. Liver Dis., 20, 17, 10.1055/s-2000-9505 Sutton, 1988, Factors affecting the prognosis of primary liver carcinoma, J. Clin. Oncol., 6, 321, 10.1200/JCO.1988.6.2.321 Selby, 1995, Liver transplantation for hepatocellular carcinoma, World J. Surg., 19, 53, 10.1007/BF00316980 Schwartz, 1995, A multidisciplinary approach to hepatocellular carcinoma in patients with cirrhosis, J. Am. Coll. Surg., 180, 596 Kirn, 2001, Replication-selective virotherapy for cancer: Biological principles, risk management and future directions, Nat. Med., 7, 781, 10.1038/89901 Stojdl, 2000, The murine double-stranded RNA-dependent protein kinase PKR is required for resistance to vesicular stomatitis virus, J. Virol., 74, 9580, 10.1128/JVI.74.20.9580-9585.2000 Lorence, 1994, Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy, Cancer Res., 54, 6017 Coffey, 1998, Reovirus therapy of tumors with activated Ras pathway, Science, 282, 1332, 10.1126/science.282.5392.1332 Peng, 2001, Systemic therapy of myeloma xenografts by an attenuated measles virus, Blood, 98, 2002, 10.1182/blood.V98.7.2002 Stojdl, 2000, Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus, Nat. Med., 6, 821, 10.1038/77558 Letchworth, 1999, Vesicular stomatitis, Vet. J., 157, 239, 10.1053/tvjl.1998.0303 Rose, 2001, Rhabdoviridae: the viruses and their replication, 1221 Ebert, 2003, Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats, Cancer Res., 63, 3605 Reid, 2002, Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints, Cancer Res., 62, 6070 Mohr, 2002, Gene therapy for malignant liver disease, Expert Opin. Biol. Ther., 2, 163, 10.1517/14712598.2.2.163 Gerolami, 1998, Enhanced in vivo adenovirus-mediated gene transfer to rat hepatocarcinomas by selective administration into the hepatic artery artery, Gene Ther., 5, 896, 10.1038/sj.gt.3300664 Anderson, 1998, p53 gene therapy in a rat model of hepatocellular carcinoma: intra-arterial delivery of a recombinant adenovirus, Clin. Cancer Res., 4, 1649 Bilbao, 2000, A blood–tumor barrier limits gene transfer to experimental liver cancer: the effect of vasoactive compounds, Gene Ther., 7, 1824, 10.1038/sj.gt.3301312 Vollmer, 1999, p53 selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma, Cancer Res., 59, 4369 Hallenbeck, 1999, A novel tumor tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma, Hum. Gene Ther., 10, 1721, 10.1089/10430349950017725 Huang, 2003, Telomerase-dependent oncolytic adenovirus for cancer treatment, Gene Ther., 10, 1241, 10.1038/sj.gt.3301987 Miyatake, 1999, Hepatoma-specific antitumor activity of an albumin enhancer/promoter regulated herpes simplex virus in vivo, Gene Ther., 6, 564, 10.1038/sj.gt.3300861 Pawlik, 2000, Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpesvirus, Cancer Res., 60, 2790 Moehler, 2001, Effective infection, apoptotic cell killing and gene transfer of human hepatoma cells but not primary hepatocytes by parvovirus H1 and derived vectors, Cancer Gene Ther., 8, 158, 10.1038/sj.cgt.7700288 Fuller, 1984, Vesicular stomatitis virus infects and matures only through the basolateral surface of the polarized epithelial cell line, MDCK, Cell, 38, 65, 10.1016/0092-8674(84)90527-0 Gobet, 1988, The role of antibodies in natural and acquired resistance of mice to vesicular stomatitis virus, Exp. Cell Biol., 56, 175 Ochsenbein, 1999, Control of early viral and bacterial distribution and disease by natural antibodies, Science, 286, 2156, 10.1126/science.286.5447.2156 Charan, 1986, Antibody mediated suppression of secondary IgM response in nude mice against vesicular stomatitis virus, J. Immunol., 136, 3057, 10.4049/jimmunol.136.8.3057 Kundig, 1993, Immune responses in interleukin-2-deficient mice, Science, 262, 1059, 10.1126/science.8235625 Steinhauer, 1989, High nucleotide substitution error frequencies in clonal pools of vesicular stomatitis virus, J. Virol., 63, 2063, 10.1128/JVI.63.5.2063-2071.1989 Schnell, 1996, The minimal conserved transcription stop–start signal promotes stable expression of a foreign gene in vesicular stomatitis virus, J. Virol., 70, 2318, 10.1128/JVI.70.4.2318-2323.1996 Belkowski, 1987, Inhibition of vesicular stomatitis viral mRNA synthesis by interferons, J. Virol., 61, 653, 10.1128/JVI.61.3.653-660.1987 Wildner, 1999, Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer, Gene Ther., 6, 57, 10.1038/sj.gt.3300810 Nakamura, 2001, Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil, Cancer Res., 61, 5447 Jarnagin, 2003, Neoadjuvant treatment of hepatic malignancy: an oncolytic herpes simplex virus expressing IL-12 effectively treats the parent tumor and protects against recurrence—after resection, Cancer Gene Ther., 10, 215, 10.1038/sj.cgt.7700558 Fu, 2003, Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect, Mol. Ther., 7, 748, 10.1016/S1525-0016(03)00092-3 Fernandez, 2002, Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease, J. Virol., 76, 895, 10.1128/JVI.76.2.895-904.2002 Obuchi, 2003, Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity, J. Virol., 77, 8843, 10.1128/JVI.77.16.8843-8856.2003 Stojdl, 2003, VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents, Cancer Cell, 4, 263, 10.1016/S1535-6108(03)00241-1 Lawson, 1995, Recombinant vesicular stomatitis viruses from DNA, Proc. Natl. Acad. Sci. USA, 92, 4477, 10.1073/pnas.92.10.4477 Whelan, 1995, Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones, Proc. Natl. Acad. Sci. USA, 92, 8388, 10.1073/pnas.92.18.8388